23:34 , Jun 26, 2019 |  BC Innovations  |  Distillery Therapeutics

miR-17-92 gene therapy for ALS associated with SOD1 mutations

DISEASE CATEGORY: Neurology INDICATION: Amyotrophic lateral sclerosis (ALS) A study from Taiwan's Academia Sinica suggests gene therapies encoding the miR-17-92 cluster could help treat SOD1-associated ALS. The cluster was previously reported to promote survival of...
22:58 , Apr 4, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: March 2019

New Therapeutic Targets and Biomarkers: March 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March. Therapeutic targets are defined as any protein, gene or other molecule...
13:05 , Mar 13, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting B3GALT5 or its biosynthetic products for breast and pancreatic cancers

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; pancreatic cancer Patient sample, cell culture and mouse studies suggest inhibiting B3GALT5 or its downstream biosynthetic products SSEA-4 and globo-H could help treat breast and pancreatic cancers. In tissue...
21:11 , Feb 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus Mouse studies suggest an inactivated influenza virus vaccine expressing monoglycosylated HA could help prevent infection by multiple influenza A virus strains. The vaccine consists of inactivated H1N1 influenza virus particles modified to...
23:05 , Aug 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

New Therapeutic Targets and Biomarkers: July 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2018. Therapeutic targets are defined as any protein, gene or other...
17:36 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest inhibiting CBLC could help treat EGFR-mutant NSCLC. In two human EGFR-mutant NSCLC cell lines, two shRNAs targeting CBLC decreased viability compared with a...
19:50 , Aug 18, 2017 |  BC Week In Review  |  Company News

Aslan and Academia Sinica combine ASLAN003 and varlitinib in animal models

Aslan Pharmaceuticals Ltd. (TPEx:6497) and Academia Sinica (Taipei, Taiwan) partnered to evaluate the the combination of varlitinib ( ASLAN001 ) and ASLAN003 in animal models for gastric, colorectal and lung cancers. The partners said the...
22:01 , Apr 4, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Patient sample, cell culture and mouse studies suggest inhibiting HER2 could help treat AD. In postmortem hippocampal tissue samples, levels of HER2 were higher in samples from sporadic AD patients than...
19:08 , Jan 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest promoting DAXX expression could help treat lung cancer. In patients with non-small cell lung cancer (NSCLC) tumors that overexpressed the metastasis-promoting SNAI2 gene, low...
20:01 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Patient sample, cell culture and mouse studies suggest inhibiting TIFA could help treat AML. In peripheral blood mononuclear cells (PBMCs) from AML patients, levels of TIFA were higher in than...